You are United State Andy Slavitt, the country’s government advisor on Covid-19, said a batch of 60 million doses of the Oxford / AstraZeneca vaccine will reach other countries as soon as the required quantity arrives.
The United States to share up to 60 million doses of AstraZeneca vaccine
The country is now facing pressure to increase the number of recipients of its donations, especially to India.
The Oxford / AstraZeneca vaccine has not been authorized by the Food and Drug Administration (FDA), the agency responsible for this type of authorization in the United States.
The US government is confident the country has adequate doses with the three suppliers that have so far received vaccines: Johnson & Johnson, Pfizer and Modern.
White House Coordinator Jeff Zentes said, “Given that we have a robust suite of vaccines that have already been authorized by the Food and Drug Administration and that AstraZeneca has not been launched, we do not need AstraZeneca doses in the coming months.”
The United States is also studying which countries will receive the doses and also how to share these vaccines with other countries.
About 10 million doses of AstraZeneca vaccine have been produced in the United States, but they are not authorized by the Food and Drug Administration. Another 50 million are still in production, and it is expected to be available between May and June. The United States purchased 300 million doses of AstraZeneca.
The vaccine has been the subject of some questions since the end of last year, although it has been licensed for use by dozens of countries, including Brazil, and European authoritiesAs well as the Brazilian, in addition to Many international scholars e And OMS They testified that their safety and benefit far outweigh any risks related to the very rare cases of immune-related thrombosis.
Anthony Fauci, director of the US National Institute of Allergy and Infectious Diseases, said recently that the United States has sufficient contracts with other vaccine manufacturers to fully immunize its population and may be sufficient to boost vaccination in the future.
When asked if the United States would use doses of AstraZeneca vaccine, he said, “This is still in the air. My general feeling is that, given the contractual relationships that we have with many companies, we have enough vaccine to meet all our needs without relying on AstraZeneca.”
At the end of last year, the lab and the University of Oxford published data from a clinical trial with two different readings of efficacy due to an error in dosing. In March, more than a dozen countries stopped using the AstraZeneca vaccine temporarily after reports linking it to a rare blood clotting disorder.
Also in March, a US health agency said the company’s data provided an incomplete picture of its effectiveness. Days later, AstraZeneca published results showing less efficacy, although still going strong.
In the country, the manufacturer responsible for dosing AstraZeneca was Emergent BioSolutions, from Baltimore.
This manufacturer had problems producing another vaccine, Johnson & Johnson. After that episode, the US government sent Johnson & Johnson to manage the production facility to ensure product quality.
The United States has also ordered the plant to stop producing doses of AstraZeneca, which is looking elsewhere to be able to manufacture its vaccine in the country.